$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2012 Q3 Form 10-Q Financial Statement

#000119312512338041 Filed on August 06, 2012

Income Statement

Concept	2012 Q3	2012 Q2	2011 Q2
Revenue	$23.10M	$23.50M	$21.40M
YoY Change	26.23%	9.81%	81.36%
Cost Of Revenue	$14.70M	$12.20M	$9.546M
YoY Change	45.69%	27.8%	30.77%
Gross Profit	$8.400M	$11.20M	$11.90M
YoY Change	2.44%	-5.88%	164.44%
Gross Profit Margin	36.36%	47.66%	55.61%
Selling, General & Admin	$15.40M	$15.90M	$12.24M
YoY Change	16.31%	29.86%	17.73%
% of Gross Profit	183.33%	141.96%	102.89%
Research & Development	$10.30M	$10.00M	$7.016M
YoY Change	25.14%	42.53%	29.93%
% of Gross Profit	122.62%	89.29%	58.96%
Depreciation & Amortization	$2.100M	$1.500M	$900.0K
YoY Change	110.0%	66.67%	50.0%
% of Gross Profit	25.0%	13.39%	7.56%
Operating Expenses	$25.70M	$25.90M	$19.30M
YoY Change	19.53%	34.2%	22.15%
Operating Profit	-$17.30M	-$14.70M	-$7.389M
YoY Change	30.0%	98.94%	-34.61%
Interest Expense	$0.00	$0.00	$3.000K
YoY Change	-100.0%	-100.0%	-101.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$17.30M	-$14.70M	-$7.367M
YoY Change	30.29%	99.54%	-37.03%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$17.30M	-$14.70M	-$7.400M
YoY Change	30.08%	98.65%	-36.75%
Net Earnings / Revenue	-74.89%	-62.55%	-34.58%
Basic Earnings Per Share
Diluted Earnings Per Share	-$250.4K	-$214.3K	-$113.7K
COMMON SHARES
Basic Shares Outstanding	69.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q3	2012 Q2	2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$53.34M	$61.20M	$105.0M
YoY Change	-45.18%	-41.71%	161.85%
Cash & Equivalents	$4.700M	$6.000M	$33.89M
Short-Term Investments	$48.64M	$55.20M	$71.10M
Other Short-Term Assets	$2.700M	$2.500M	$4.000M
YoY Change	8.0%	-37.5%	150.0%
Inventory	$7.141M	$7.378M	$6.300M
Prepaid Expenses
Receivables	$12.40M	$12.90M	$8.700M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$75.57M	$83.99M	$124.0M
YoY Change	-34.4%	-32.26%	146.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.61M	$17.77M	$12.00M
YoY Change	48.9%	48.07%	53.85%
Goodwill	$3.162M	$3.162M
YoY Change
Intangibles	$4.313M	$4.462M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$98.00K	$98.00K	$400.0K
YoY Change	-90.2%	-75.5%	-82.61%
Total Long-Term Assets	$27.23M	$26.53M	$12.40M
YoY Change	100.18%	113.94%	21.57%
TOTAL ASSETS
Total Short-Term Assets	$75.57M	$83.99M	$124.0M
Total Long-Term Assets	$27.23M	$26.53M	$12.40M
Total Assets	$102.8M	$110.5M	$136.4M
YoY Change	-20.19%	-18.97%	125.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.800M	$2.000M	$2.100M
YoY Change	40.74%	-4.76%	-4.55%
Accrued Expenses	$15.40M	$13.40M	$9.300M
YoY Change	48.08%	44.09%	10.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$100.0K
YoY Change			-88.89%
Total Short-Term Liabilities	$20.40M	$16.96M	$13.80M
YoY Change	38.8%	22.91%	-10.97%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.570M	$1.551M	$1.000M
YoY Change	57.0%	55.1%	25.0%
Total Long-Term Liabilities	$1.570M	$1.551M	$1.000M
YoY Change	57.0%	55.1%	-75.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.40M	$16.96M	$13.80M
Total Long-Term Liabilities	$1.570M	$1.551M	$1.000M
Total Liabilities	$22.54M	$19.21M	$14.80M
YoY Change	43.59%	29.82%	-24.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$437.1M	-$419.9M
YoY Change
Common Stock	$517.4M	$511.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$80.30M	$91.30M	$121.6M
YoY Change
Total Liabilities & Shareholders Equity	$102.8M	$110.5M	$136.4M
YoY Change	-20.19%	-18.97%	125.08%

Cashflow Statement

Concept	2012 Q3	2012 Q2	2011 Q2
OPERATING ACTIVITIES
Net Income	-$17.30M	-$14.70M	-$7.400M
YoY Change	30.08%	98.65%	-36.75%
Depreciation, Depletion And Amortization	$2.100M	$1.500M	$900.0K
YoY Change	110.0%	66.67%	50.0%
Cash From Operating Activities	-$6.000M	-$6.300M	-$2.500M
YoY Change	-11.76%	152.0%	-73.12%
INVESTING ACTIVITIES
Capital Expenditures	-$2.900M	-$2.900M	-$1.200M
YoY Change	93.33%	141.67%	-14.29%
Acquisitions
YoY Change
Other Investing Activities	$6.300M	$9.600M	-$38.00M
YoY Change	-169.23%	-125.26%	-860.0%
Cash From Investing Activities	$3.400M	$6.800M	-$39.10M
YoY Change	-132.08%	-117.39%	-1217.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.300M	500.0K	71.70M
YoY Change	44.44%	-99.3%	5875.0%
NET CHANGE
Cash From Operating Activities	-6.000M	-6.300M	-2.500M
Cash From Investing Activities	3.400M	6.800M	-39.10M
Cash From Financing Activities	1.300M	500.0K	71.70M
Net Change In Cash	-1.300M	1.000M	30.10M
YoY Change	-92.12%	-96.68%	-754.35%
FREE CASH FLOW
Cash From Operating Activities	-$6.000M	-$6.300M	-$2.500M
Capital Expenditures	-$2.900M	-$2.900M	-$1.200M
Free Cash Flow	-$3.100M	-$3.400M	-$1.300M
YoY Change	-41.51%	161.54%	-83.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69029287	shares
CY2012Q1	us-gaap	Business Acquisition Equity Interest Issued Or Issuable Value Assigned BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned	3900000
CY2012Q1	us-gaap	Business Acquisition Contingent Consideration At Fair Value BusinessAcquisitionContingentConsiderationAtFairValue	2200000
CY2011Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	469000
CY2011Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33889000
CY2011Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	446000
CY2011Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2012Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	341000
CY2012Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2235000
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7532000
CY2012Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	933000
CY2012Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	91308000
CY2012Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7930000
CY2012Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	61200000
CY2012Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q2	us-gaap	Business Acquisition Cost Of Acquired Entity Purchase Price BusinessAcquisitionCostOfAcquiredEntityPurchasePrice	6063000
CY2012Q2	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	9000
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-88000
CY2012Q2	us-gaap	Marketable Securities MarketableSecurities	55203000
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16961000
CY2012Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2527000
CY2012Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1039000
CY2012Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1499000
CY2012Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-419879000
CY2012Q2	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	11000000
CY2012Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	380000
CY2012Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2268000
CY2012Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	98000
CY2012Q2	us-gaap	Assets Assets	110522000
CY2012Q2	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	2000
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5985000
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2511000
CY2012Q2	us-gaap	Valuation Allowance Amount ValuationAllowanceAmount	134700000
CY2012Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0
CY2012Q2	us-gaap	Inventory Net InventoryNet	7378000
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	110522000
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69189000	shares
CY2012Q2	us-gaap	Business Acquisition Cost Of Acquired Entity Other Noncash Consideration BusinessAcquisitionCostOfAcquiredEntityOtherNoncashConsideration	2181000
CY2012Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	55203000
CY2012Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2021000
CY2012Q2	us-gaap	Goodwill Goodwill	3162000
CY2012Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	55210000
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2591000
CY2012Q2	us-gaap	Liabilities Liabilities	19214000
CY2012Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1039000
CY2012Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4462000
CY2012Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4177000
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2507000
CY2012Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Business Acquisition Purchase Price Allocation Amortizable Intangible Assets BusinessAcquisitionPurchasePriceAllocationAmortizableIntangibleAssets	4600000
CY2012Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17768000
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1150000
CY2012Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68905000	shares
CY2012Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	69000
CY2012Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	702000
CY2012Q2	us-gaap	Assets Current AssetsCurrent	83993000
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	11424000
CY2012Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	35600000
CY2012Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3258000
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	511206000
CY2012Q2	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Amount BusinessAcquisitionPurchasePriceAllocationGoodwillAmount	3200000
CY2012Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1551000
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1695000
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2665000
CY2012Q2	dxcm	Contingent Consideration Fair Value Disclosure ContingentConsiderationFairValueDisclosure	1695000
CY2012Q2	dxcm	Clinical Trials ClinicalTrials	125000
CY2012Q2	dxcm	Business Acquisition Contingent Consideration Amounts Payable BusinessAcquisitionContingentConsiderationAmountsPayable	1100000
CY2012Q2	dxcm	Market Value Of Common Stock Issued On Closing MarketValueOfCommonStockIssuedOnClosing	3882000
CY2012Q2	dxcm	Working Capital WorkingCapital	67000000
CY2012Q2	dxcm	Unrecognized Share Based Compensation Relate To Performance Awards UnrecognizedShareBasedCompensationRelateToPerformanceAwards	1300000
CY2012Q2	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	12900000
CY2012Q2	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	832000
CY2012Q2	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	1	Year
CY2012Q2	dxcm	Business Acquisition Contingent Consideration Settlement Shares Issued BusinessAcquisitionContingentConsiderationSettlementSharesIssued	89296	shares
CY2012Q2	dxcm	Acquisition Related Contingent Consideration Short Term AcquisitionRelatedContingentConsiderationShortTerm	1296000
CY2012Q2	dxcm	Business Acquisition Contingent Consideration Settlement BusinessAcquisitionContingentConsiderationSettlement	1100000
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4889000
CY2010Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	435000
CY2010Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2011Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6346000
CY2011Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	601000
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	104490000
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6804000
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	14000
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-80000
CY2011Q4	us-gaap	Marketable Securities MarketableSecurities	79358000
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14741000
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1781000
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	939000
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1591000
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-391124000
CY2011Q4	us-gaap	Assets Assets	120475000
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	13000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2553000
CY2011Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0
CY2011Q4	us-gaap	Inventory Net InventoryNet	8171000
CY2011Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	306000
CY2011Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2993000
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	107000
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	120475000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67833000	shares
CY2011Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	79358000
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2011Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2807000
CY2011Q4	us-gaap	Goodwill Goodwill	0
CY2011Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	79359000
CY2011Q4	us-gaap	Liabilities Liabilities	15985000
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	939000
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0
CY2011Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4577000
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15019000
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67549000	shares
CY2011Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	68000
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	281000
CY2011Q4	us-gaap	Assets Current AssetsCurrent	104410000
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2643000
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	495626000
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	963000
CY2011Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2011Q4	dxcm	Clinical Trials ClinicalTrials	161000
CY2011Q4	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	12547000
CY2011Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	735000
CY2011Q4	dxcm	Acquisition Related Contingent Consideration Short Term AcquisitionRelatedContingentConsiderationShortTerm	0
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1698000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	49430000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32323000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	51000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13284000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1191000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2023000
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0
	us-gaap	Share Based Compensation ShareBasedCompensation	6205000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	29000000
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-24000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1400000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19259000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1854000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	16703000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-316000
	us-gaap	Net Income Loss NetIncomeLoss	-19217000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	673000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	73179000
	us-gaap	Gross Profit GrossProfit	16987000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19252000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	0
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	171000
	us-gaap	Operating Expenses OperatingExpenses	36246000
	us-gaap	Revenues Revenues	35591000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22962000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-41000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-385000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2951000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	0
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	28318000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	20058000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6200000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19217000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9814000	shares
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	450000
	us-gaap	Interest Expense InterestExpense	9000
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	73629000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-41000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11815000
	us-gaap	Cost Of Revenue CostOfRevenue	18604000
	dxcm	Weighted Average Number Of Outstanding Shares Basic And Diluted WeightedAverageNumberOfOutstandingSharesBasicAndDiluted	63646000	shares
	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	1901000
	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	7273000
	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	0
	dxcm	Increase Decrease In Restricted Cash Investing And Financing Activities IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities	450000
	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	983000
	dxcm	Standard Product Warranty Accrual Costs Incurred StandardProductWarrantyAccrualCostsIncurred	972000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2012-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Trading Symbol TradingSymbol	dxcm
	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2650000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	42283000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18353000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	48000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20213000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	329000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	353000
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1316000
	us-gaap	Share Based Compensation ShareBasedCompensation	8979000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3432000
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	87000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1100000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30046000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1000
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Organization and Business</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (“CGM”) systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.</font></p> </div>
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-793000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	20476000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-498000
	us-gaap	Net Income Loss NetIncomeLoss	-28755000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1126000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1572000
	us-gaap	Gross Profit GrossProfit	20630000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-8000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28763000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	2181000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	643000
	us-gaap	Operating Expenses OperatingExpenses	50676000
	us-gaap	Revenues Revenues	43545000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30463000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1244000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-451000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5202000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	662000
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	40142000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	65838000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9000000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29999000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10734000	shares
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1148000
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, warranty accruals, employee bonus, clinical study expenses, allowances for returned product, allowance for bad debt, deferral period for recognizing revenue on future performance obligations, accounting for the SweetSpot acquisition, and share-based compensation expense. Excess and obsolete inventories are estimated by identifying the amount of on hand and on order materials compared to expected future sales, taking into account clinical trial and development usage along with new product introductions. Employee bonus estimates are based, in part, on the 2012 bonus plan’s authorized target bonus amounts to be awarded from the bonus pool based on the weighted average achievement of certain objectives. Clinical trial expenses are accrued based on estimates of progress under related contracts and include initial set up costs as well as ongoing monitoring over multiple sites in the U.S. and abroad. An allowance for refunds for returned products is determined by analyzing the timing and amounts of past refund activity.</font></p> </div>
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0
	us-gaap	Interest Expense InterestExpense	1000
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	6063000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1572000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16493000
	us-gaap	Acquisition Costs AcquisitionCosts	300000
	us-gaap	Cost Of Revenue CostOfRevenue	22915000
	dxcm	Weighted Average Number Of Outstanding Shares Basic And Diluted WeightedAverageNumberOfOutstandingSharesBasicAndDiluted	68212000	shares
	dxcm	Option To Renew Lease OptionToRenewLease	5	Year
	dxcm	Warranty Coverage Period WarrantyCoveragePeriod	30	Day
	dxcm	Term Of Lease TermOfLease	3	Year
	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	2439000
	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	3403000
	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	662000
	dxcm	Increase Decrease In Restricted Cash Investing And Financing Activities IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities	-100000
	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	1020000
	dxcm	Standard Product Warranty Accrual Costs Incurred StandardProductWarrantyAccrualCostsIncurred	946000
	dxcm	Maximum Percentage Of Ownership To Retain Tax Credit Carryforwards MaximumPercentageOfOwnershipToRetainTaxCreditCarryforwards	0.50	pure
	dxcm	Potential Rental Rate Adjustment Maximum PotentialRentalRateAdjustmentMaximum	0.04	pure
	dxcm	Potential Rental Rate Adjustment Minimum PotentialRentalRateAdjustmentMinimum	0.025	pure
CY2011Q2	us-gaap	Operating Expenses OperatingExpenses	19260000
CY2011Q2	us-gaap	Revenues Revenues	21417000
CY2011Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12244000
CY2011Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2011Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	0
CY2011Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	15179000
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2011Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	25000
CY2011Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7016000
CY2011Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7389000
CY2011Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	8351000
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-7367000
CY2011Q2	us-gaap	Gross Profit GrossProfit	11871000
CY2011Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-11000
CY2011Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7385000
CY2011Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	0
CY2011Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3600000
CY2011Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7367000
CY2011Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9814000	shares
CY2011Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0
CY2011Q2	us-gaap	Interest Expense InterestExpense	3000
CY2011Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-7000
CY2011Q2	us-gaap	Cost Of Revenue CostOfRevenue	9546000
CY2011Q2	dxcm	Weighted Average Number Of Outstanding Shares Basic And Diluted WeightedAverageNumberOfOutstandingSharesBasicAndDiluted	65096000	shares
CY2011Q2	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	1195000
CY2011Q2	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	6238000
CY2011Q2	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	471000
CY2011Q2	dxcm	Standard Product Warranty Accrual Costs Incurred StandardProductWarrantyAccrualCostsIncurred	494000
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	23000
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10498000
CY2012Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14649000
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10889000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-14691000
CY2012Q2	us-gaap	Gross Profit GrossProfit	11243000
CY2012Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-6000
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14676000
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	0
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	25892000
CY2012Q2	us-gaap	Revenues Revenues	23450000
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15394000
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	608000
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	21524000
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4800000
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14627000
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10734000	shares
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1148000
CY2012Q2	us-gaap	Interest Expense InterestExpense	1000
CY2012Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	21000
CY2012Q2	us-gaap	Acquisition Costs AcquisitionCosts	100000
CY2012Q2	us-gaap	Cost Of Revenue CostOfRevenue	12207000
CY2012Q2	dxcm	Weighted Average Number Of Outstanding Shares Basic And Diluted WeightedAverageNumberOfOutstandingSharesBasicAndDiluted	68635000	shares
CY2012Q2	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	1318000
CY2012Q2	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	1926000
CY2012Q2	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	539000
CY2012Q2	dxcm	Standard Product Warranty Accrual Costs Incurred StandardProductWarrantyAccrualCostsIncurred	500000

Files In Submission

Name	View Source	Status
0001193125-12-338041-index-headers.html	Edgar Link	pending
0001193125-12-338041-index.html	Edgar Link	pending
0001193125-12-338041.txt	Edgar Link	pending
0001193125-12-338041-xbrl.zip	Edgar Link	pending
d370079d10q.htm	Edgar Link	pending
d370079dex3101.htm	Edgar Link	pending
d370079dex3102.htm	Edgar Link	pending
d370079dex3201.htm	Edgar Link	pending
d370079dex3202.htm	Edgar Link	pending
dxcm-20120630.xml	Edgar Link	completed
dxcm-20120630.xsd	Edgar Link	pending
dxcm-20120630_cal.xml	Edgar Link	unprocessable
dxcm-20120630_def.xml	Edgar Link	unprocessable
dxcm-20120630_lab.xml	Edgar Link	unprocessable
dxcm-20120630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2012 Q3 Form 10-Q Financial Statement

#000119312512338041 Filed on August 06, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2012 Q3 Form 10-Q Financial Statement

#000119312512338041 Filed on August 06, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm